Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARTEMIS: SGT-501 in Catecholaminergic Polymorphic Ventricular Tachycardia
NCT07148089Phase 1Recruiting
- Sponsor
- Solid Biosciences
- Start
- Feb 2026
- Primary completion
- Jun 2027
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 2
01
Overview
Phase 1, open-label trial of SGT-501 in catecholaminergic polymorphic ventricular tachycardia (CPVT) (3 cohorts), sponsored by Solid Biosciences. Primary endpoint: Treatment-Emergent Adverse Events at Day 360. Started Feb 2026; status: recruiting.
02
Drugs
SGT-501
03
Conditions
catecholaminergic polymorphic ventricular tachycardia (CPVT)
Beyond the preview
Go deeper on NCT07148089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07148089.